» Articles » PMID: 36553343

Identification of the Rare Ala871Glu Mutation in the Androgen Receptor Gene Leading to Complete Androgen Insensitivity Syndrome in an Adolescent Girl with Primary Amenorrhea

Overview
Specialty Health Services
Date 2022 Dec 23
PMID 36553343
Authors
Affiliations
Soon will be listed here.
Abstract

Complete Androgen Insensitivity Syndrome (CAIS) is a rare genetic condition by mutations in the androgen receptor (AR) gene resulting in target issue resistance to androgens and a female phenotype in genetically male individuals. A 16-year-old phenotypically female individual presented to our clinic with primary amenorrhea. Her clinical evaluation showed normal female external genitalia, Tanner III breast development and sparse pubic and axillary hair (Tanner stage II). Hormonal assessment revealed increased concentrations of Luteinizing Hormone (LH), Testosterone and Antimüllerian Hormone (AMH). Image studies detected no uterus or gonads, but a blind vagina and the karyotype was 46, XY. These findings suggested the diagnosis of CAIS, and genetic testing of the AR gene revealed a rare pathogenic mutation of cytosine to adenine (c.2612C>A) replacing alanine with glutamic acid at position 871 (p.Ala871Glu) in the AR, previously described once in two adult sisters. The patient underwent gonadectomy and received hormonal replacement therapy. This study expands the AR mutation database and shows the complexity and the importance of prompt diagnosis, proper management, and follow-up for CAIS patients, underlining the need for standardized protocols.

Citing Articles

Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics.

Effah W, Khalil M, Hwang D, Miller D, Narayanan R Steroids. 2024; 210:109486.

PMID: 39111362 PMC: 11380798. DOI: 10.1016/j.steroids.2024.109486.

References
1.
Parisi M, Ramsdell L, Burns M, Carr M, Grady R, Gunther D . A Gender Assessment Team: experience with 250 patients over a period of 25 years. Genet Med. 2007; 9(6):348-57. DOI: 10.1097/gim.0b013e3180653c47. View

2.
Costagliola G, Cosci O di Coscio M, Masini B, Baldinotti F, Caligo M, Tyutyusheva N . Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre. J Endocrinol Invest. 2020; 44(1):145-151. DOI: 10.1007/s40618-020-01284-8. View

3.
Tremblay R, Foley Jr T, Corvol P, Park I, KOWARSKI A, BLIZZARD R . Plasma concentration of testosterone, dihydrotestosterone, testosterone-oestradiol binding globulin, and pituitary gonadotrophins in the syndrome of male pseudo-hermaphroditism with testicular feminization. Acta Endocrinol (Copenh). 1972; 70(2):331-41. DOI: 10.1530/acta.0.0700331. View

4.
Gava G, Mancini I, Orsili I, Bertelloni S, Alvisi S, Seracchioli R . Bone mineral density, body composition and metabolic profiles in adult women with complete androgen insensitivity syndrome and removed gonads using oral or transdermal estrogens. Eur J Endocrinol. 2019; 181(6):711-718. DOI: 10.1530/EJE-19-0383. View

5.
Boehmer A, Brinkmann O, Bruggenwirth H, van Assendelft C, Otten B, Niermeijer M . Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab. 2001; 86(9):4151-60. DOI: 10.1210/jcem.86.9.7825. View